The migraine medication erenumab appeared to pose no increased risk of hypertension, easing earlier concerns. Nevertheless, investigators noted that more research is needed to confirm the findings.

Erenumab, approved in 2018 for migraine prevention, is designed to block the calcitonin gene-related peptide (CGRP) receptor. CGRP is a potent vasodilator, and vascular dysfunction is believed to ...

Erenumab, a monoclonal antibody that was first approved in 2018, is administered monthly via self-injection of a 70- or 140-mg dose. The treatment blocks the calcitonin gene-related peptide ...

Patients with prior preventive treatment failures for migraine were shown to benefit more from a higher dose of erenumab (140 mg) versus a lower dose (70 mg), according to study findings.

Findings showed that treatment with erenumab-aooe was associated with a significantly lower discontinuation rate due to adverse events compared with topiramate (10.6% vs 38.9%).

Erenumab was the first drug of a new drug class for the prophylaxis of migraine to enter the German market in November 2018. In an early benefit assessment, the German Institute for Quality and ...

Erenumab was the first drug of a new drug class for the prophylaxis of migraine to enter the German market in November 2018. In an early benefit assessment, the German Institute for Quality and ...

LIBERTY is the first migraine prevention trial of its kind conducted specifically in patients who have tried multiple therapies without success, and are in need of additional treatment options The ...

FDA: hypertension seen in some erenumab patients. The FAERS analysis evaluated reports of erenumab-associated elevated blood pressure submitted from May 17, 2018 through April 30, 2020.

Erenumab (Aimovig, Amgen), a novel antibody that targets the calcitonin gene–related peptide (CGRP) receptor, is safe and effective in patients with episodic migraine for whom other therapies ...

Erenumab is potentially efficacious in treating chronic flushing and erythema associated with rosacea, according to a study. “Rosacea is a common, chronic facial skin disease, often ...

What is new migraine drug Erenumab, is it available in the UK on the NHS and how does the jab work? Lydia Hawken; Published: 13:11, 31 Jul 2018; Updated: 13:12, 31 Jul 2018; ...